Monopar Therapeutics (MNPR) News Today $100.96 +2.39 (+2.42%) Closing price 04:00 PM EasternExtended Trading$101.52 +0.56 (+0.55%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Monopar Therapeutics (NASDAQ:MNPR) Hits New 1-Year High - Time to Buy?October 6 at 11:29 AM | marketbeat.comMonopar Therapeutics price target raised to $142 from $80 at Raymond JamesOctober 6 at 10:51 AM | msn.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Receives $86.22 Average PT from BrokeragesOctober 4, 2025 | americanbankingnews.comOppenheimer Maintains Monopar Therapeutics (MNPR) Outperform RecommendationOctober 3, 2025 | msn.comMonopar Therapeutics price target raised to $115 from $77 at OppenheimerOctober 2, 2025 | msn.comMonopar Therapeutics (NASDAQ:MNPR) Shares Gap Up - Here's What HappenedOctober 2, 2025 | marketbeat.comHC Wainwright Has Strong Forecast for MNPR FY2027 EarningsOctober 2, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for MNPR FY2027 Earnings?October 1, 2025 | marketbeat.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Buy" from AnalystsOctober 1, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Reaches New 1-Year High - Still a Buy?September 30, 2025 | marketbeat.comMonopar Therapeutics (MNPR) Price Target Increased by 18.34% to 99.28September 30, 2025 | msn.comAnalysts Issue Forecasts for MNPR Q1 EarningsSeptember 30, 2025 | americanbankingnews.comMonopar Therapeutics price target raised to $105 from $70 at H.C. WainwrightSeptember 29, 2025 | msn.comBrokers Set Expectations for MNPR Q1 EarningsSeptember 29, 2025 | marketbeat.comMNPR FY2025 EPS Estimate Lifted by Cantor FitzgeraldSeptember 29, 2025 | americanbankingnews.comMNPR FY2025 EPS Forecast Lifted by Cantor FitzgeraldSeptember 29, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Major Shareholder Tactic Pharma Llc Sells 550,229 SharesSeptember 26, 2025 | marketbeat.comChardan Capital Maintains Monopar Therapeutics (MNPR) Buy RecommendationSeptember 25, 2025 | msn.comMonopar Therapeutics (NASDAQ:MNPR) Given New $85.00 Price Target at Chardan CapitalSeptember 25, 2025 | marketbeat.comBTIG Research Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) StockSeptember 25, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Upgraded to Strong-Buy at Lake Street CapitalSeptember 25, 2025 | marketbeat.comGoldman Sachs Group Inc. Takes $673,000 Position in Monopar Therapeutics Inc. $MNPRSeptember 25, 2025 | marketbeat.comLake Street Initiates Coverage of Monopar Therapeutics (MNPR) with Buy RecommendationSeptember 24, 2025 | msn.comMonopar Therapeutics Inc. Announces Pricing of $100 Million Registered Offering of Common Stock and Pre-Funded WarrantsSeptember 23, 2025 | quiverquant.comQMonopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsSeptember 23, 2025 | globenewswire.comMonopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease PatientsSeptember 23, 2025 | globenewswire.comMonopar Therapeutics initiated with a Buy at Lake StreetSeptember 23, 2025 | msn.comMonopar Therapeutics (NASDAQ:MNPR) Given Buy Rating at Chardan CapitalSeptember 17, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from BTIG ResearchSeptember 16, 2025 | marketbeat.comPromising Long-Term Efficacy and Safety of ALXN1840 Strengthens Buy Rating for Monopar Therapeutics Inc.September 16, 2025 | tipranks.comWhy Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A BreakoutSeptember 15, 2025 | msn.comMonopar Therapeutics Presents New Data on ALXN1840September 15, 2025 | tipranks.comMonopar Therapeutics announces new data from study of ALXN1840September 14, 2025 | msn.comMonopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual MeetingSeptember 14, 2025 | globenewswire.comBTIG Research Begins Coverage on Monopar Therapeutics (NASDAQ:MNPR)September 11, 2025 | marketbeat.comMonopar Therapeutics initiated with a Buy at BTIGSeptember 9, 2025 | msn.comBTIG Initiates Coverage of Monopar Therapeutics (MNPR) with Buy RecommendationSeptember 9, 2025 | msn.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 8, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Takes Position in Monopar Therapeutics Inc. $MNPRSeptember 6, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Coverage Initiated at OppenheimerSeptember 5, 2025 | marketbeat.comOppenheimer Initiates Coverage of Monopar Therapeutics (MNPR) with Outperform RecommendationSeptember 4, 2025 | msn.comADAR1 Capital Management LLC Has $3.67 Million Holdings in Monopar Therapeutics Inc. $MNPRSeptember 4, 2025 | marketbeat.comRaymond James Initiates Coverage of Monopar Therapeutics (MNPR) with Strong Buy RecommendationSeptember 4, 2025 | msn.comMonopar Therapeutics initiated with an Outperform at OppenheimerSeptember 3, 2025 | msn.comOppenheimer starts Monopar with Outperform on ALXN1840 potentialSeptember 3, 2025 | msn.comMonopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual MeetingSeptember 3, 2025 | globenewswire.comMonopar Therapeutics initiated with a Strong Buy at Raymond JamesSeptember 2, 2025 | msn.comQ3 Earnings Estimate for MNPR Issued By HC WainwrightAugust 30, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Given Overweight Rating at Cantor FitzgeraldAugust 29, 2025 | marketbeat.comAffinity Asset Advisors LLC Buys Shares of 62,000 Monopar Therapeutics Inc. $MNPRAugust 28, 2025 | marketbeat.com Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MNPR Media Mentions By Week MNPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNPR News Sentiment▼0.490.77▲Average Medical News Sentiment MNPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNPR Articles This Week▼74▲MNPR Articles Average Week Get the Latest News and Ratings for MNPR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Monopar Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies IDEAYA Biosciences News Belite Bio News ImmunityBio News Arcutis Biotherapeutics News Recursion Pharmaceuticals News Mesoblast News Disc Medicine News Agios Pharmaceuticals News Denali Therapeutics News Sarepta Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNPR) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
